Depomed

Horizon withdraws offer to acquire Depomed

Monday, November 23, 2015

Horizon Pharma, a Dublin-based biopharmaceutical company, has announced that at a hearing, Judge Peter Kirwan of the Superior Court of California for the County of Santa Clara granted Depomed‘s motion for preliminary injunctive relief against Horizon Pharma’s alleged use of information that Depomed claimed was confidential. In his ruling, Judge Kirwan did not grant the injunctive relief Horizon Pharma had sought regarding the legality of Depomed’s poison pill and certain of the bylaw amendments announced by Depomed’s board of directors on July 13.

[Read More]

Horizon Pharma proposes to acquire Depomed for $3B

Wednesday, July 8, 2015

Horizon Pharma, a Dublin, Ireland-based biopharmaceutical company, has proposed to acquire all outstanding shares of Depomed, a U.S. specialty pharmaceutical company, for a per share consideration of $29.25 in an all-stock, tax-free exchange valued at approximately $3 billion. Horizon’s proposal represents a premium of 42% to the closing price of Depomed on July 6. The transaction, if consummated, would be immediately and substantially accretive to Horizon’s adjusted diluted earnings per share.

[Read More]